Transcept rejects Retrophin proposal

|By:, SA News Editor

Transcept Pharmaceuticals (TSPT) formally rejects Retrophin's (RTRX.PK) $4/share takeout bid.

TSPT says the deal "is not in the best interest of shareholders." (PR)

The company previously rejected a lower offer from Retrophin.

TSPT +5% AH